Reply to "Use of the LC16m8 Smallpox Vaccine in Immunocompromised Individuals Is Still Too Risky"

Clin Vaccine Immunol. 2015 May;22(5):605. doi: 10.1128/CVI.00055-15.

Authors

Hiroyuki Yokote¹, Yasuhiko Shinmura²

Affiliations

¹ Development Department, Vaccine Division, The Chemo-Sero-Therapeutic Research Institute (KAKETSUKEN), Kita-ku Kumamoto-shi, Kumamoto, Japan yokote@kaketsuken.or.jp.
² Development Department, Vaccine Division, The Chemo-Sero-Therapeutic Research Institute (KAKETSUKEN), Kita-ku Kumamoto-shi, Kumamoto, Japan.

No abstract available

Publication types

Letter
Comment

MeSH terms

Animals
Female
Immunocompromised Host*
Smallpox Vaccine / adverse effects*

Substances

Smallpox Vaccine